The company's most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn's disease.
Is Arena Pharmaceuticals a good buy?
Valuation metrics show that Arena Pharmaceuticals, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ARNA, demonstrate its potential to underperform the market.
How many employees does Arena Pharmaceuticals have?
Employee Data Arena Pharmaceuticals has 530 Employees.
Which companies has Pfizer bought?
- King Pharmaceuticals, $3.6 billion. Pfizer acquired King Pharmaceuticals in 2010.
- Hospira, $15.2 billion.
- Wyeth, $68 billion.
- Warner-Lambert, $90.2.
What is Arena Pharmaceuticals known for?
Arena's portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including Arena's portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseasesimmuno-inflammatory diseasesAn immune-mediated inflammatory disease (IMID) is any of a group of conditions or diseases that lack a definitive etiology, but which are characterized by common inflammatory pathways leading to inflammation, and which may result from, or be triggered by, a dysregulation of the normal immune response.https://en.wikipedia.org › wiki › Immune-mediated_inflammatImmune-mediated inflammatory diseases - Wikipedia including 13 Dec 2021
Does Pfizer own Arena Pharmaceuticals?
Pfizer (NYSE:PFE) announced in December that it plans to acquire Arena Pharmaceuticals (NASDAQ:ARNA).2 Jan 2022